Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CITIUS ONCOLOGY, INC.CTOR · Entity 6935 | Director | September 19, 2025 | December 22, 2025 |
| Citius Pharmaceuticals, Inc.CTXR · Entity 7778 | Director | November 07, 2024 | November 12, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CITIUS ONCOLOGY, INC.
Report date September 19, 2025 · Filed December 22, 2025 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 300,000 |
Reported balance
After 2025-09-19 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2025-09-19 · Grant · Acquired 300,000 · Balance 300,000 F1: Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
Citius Pharmaceuticals, Inc.
Report date November 07, 2024 · Filed November 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $0.38 · Expires 2034-11-07 | Direct | 125,000 |
Reported balance
After 2024-11-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-11-07 · Grant · Acquired 125,000 · Balance 125,000 F1: The options were granted on November 7, 2024. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $0.70 · Expires 2033-10-10 | Direct | 75,000 |
Reported balance
Holding disclosure · report date 2024-11-07 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 75,000 F2: The options are vested in full and exercisable immediately. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $1.25 · Expires 2032-10-04 | Direct | 75,000 |
Reported balance
Holding disclosure · report date 2024-11-07 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 75,000 F2: The options are vested in full and exercisable immediately. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $2.04 · Expires 2031-10-11 | Direct | 75,000 |
Reported balance
Holding disclosure · report date 2024-11-07 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 75,000 F2: The options are vested in full and exercisable immediately. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $2.00 · Expires 2031-07-22 | Direct | 15,000 |
Reported balance
Holding disclosure · report date 2024-11-07 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 15,000 F2: The options are vested in full and exercisable immediately. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $1.69 · Expires 2031-02-16 | Direct | 25,000 |
Reported balance
Holding disclosure · report date 2024-11-07 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 25,000 F2: The options are vested in full and exercisable immediately. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $1.01 · Expires 2030-10-06 | Direct | 35,000 |
Reported balance
Holding disclosure · report date 2024-11-07 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 35,000 F2: The options are vested in full and exercisable immediately. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2030-07-07 | Direct | 25,000 |
Reported balance
Holding disclosure · report date 2024-11-07 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 25,000 F2: The options are vested in full and exercisable immediately. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $0.67 · Expires 2029-10-08 | Direct | 25,000 |
Reported balance
Holding disclosure · report date 2024-11-07 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 25,000 F2: The options are vested in full and exercisable immediately. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $1.62 · Expires 2028-09-04 | Direct | 15,000 |
Reported balance
Holding disclosure · report date 2024-11-07 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 15,000 F2: The options are vested in full and exercisable immediately. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $3.45 · Expires 2027-09-13 | Direct | 10,000 |
Reported balance
Holding disclosure · report date 2024-11-07 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 10,000 F2: The options are vested in full and exercisable immediately. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.10 · Expires 2025-10-01 | Direct | 26,667 |
Reported balance
Holding disclosure · report date 2024-11-07 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 26,667 F2: The options are vested in full and exercisable immediately. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on November 7, 2024. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date.
F2: The options are vested in full and exercisable immediately.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 19, 2025 Filed Sep 23, 2025 20:10 UTC | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-090616 · ownership.xml · nonDerivative · entry 1 Dutia Suren G · CIK 0001514063 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 F1 · shares: Represents restricted stock awards granted on September 19, 2025. The shares will vest in three substantially equal installments on the first, second and third anniversaries of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. Read SEC document |
| September 19, 2025 Filed Dec 1, 2025 21:10 UTC Amendment | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-116674 · ownership.xml · nonDerivative · entry 1 Dutia Suren G · CIK 0001514063 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 F1 · shares: Represents restricted stock awards granted on September 19, 2025. The shares will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. Read SEC document |
| September 19, 2025 Filed Dec 22, 2025 21:10 UTC Amendment | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-124529 · ownership.xml · nonDerivative · entry 1 Dutia Suren G · CIK 0001514063 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 F1 · shares: Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. Read SEC document |
| December 12, 2024 Filed Dec 16, 2024 21:07 UTC | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001213900-24-109299 · ownership.xml · derivative · entry 1 Dutia Suren G · CIK 0001514063 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-12-12 F1 · derivative.exercise_date: The options were granted on December 12, 2024. The options will vest 100% on the one-year anniversary of the grant date, provided that the Optionee provides Continuous Service to the Company as of the vesting date. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 22:00 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantStock Option (Right to Purchase Common Stock) · Derivative | 125,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001213900-24-096890 · ownership.xml · derivative · entry 1 Dutia Suren G · CIK 0001514063 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-11-07 F1 · derivative.exercise_date: The options were granted on November 7, 2024. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 22:29 UTC | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001213900-24-069251 · ownership.xml · derivative · entry 1 Dutia Suren G · CIK 0001514063 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-07-05 F1 · derivative.exercise_date: This option, originally issued by Citius Oncology Sub, Inc., is 100% vested. The option was assumed by Citius Oncology, Inc. in the merger transaction, which closed August 12, 2024. Read SEC document |
| October 10, 2023 Filed Oct 12, 2023 20:15 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 75,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001013762-23-003531 · ownership.xml · derivative · entry 1 Dutia Suren G · CIK 0001514063 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-10-10 F1 · security: The options were granted on October 10, 2023. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date. F1 · derivative.exercise_date: The options were granted on October 10, 2023. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date. Read SEC document |
| October 04, 2022 Filed Oct 6, 2022 20:09 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 75,000 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001213900-22-062484 · ownership.xml · derivative · entry 1 Dutia Suren G · CIK 0001514063 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-10-04 F1 · security: The options were granted on October 4, 2022. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date. F1 · derivative.exercise_date: The options were granted on October 4, 2022. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date. Read SEC document |
| October 11, 2021 Filed Oct 13, 2021 21:25 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 75,000 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001213900-21-052675 · ownership.xml · derivative · entry 1 Dutia Suren G · CIK 0001514063 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-10-11 F1 · security: The options were granted on October 11, 2021. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date. F1 · derivative.exercise_date: The options were granted on October 11, 2021. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date. Read SEC document |
| July 22, 2021 Filed Jul 26, 2021 21:03 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 15,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001213900-21-038697 · ownership.xml · derivative · entry 1 Dutia Suren G · CIK 0001514063 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-07-22 F1 · security: The options vest in full on July 22, 2022. F1 · derivative.exercise_date: The options vest in full on July 22, 2022. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 21:09 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 25,000 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001213900-21-010320 · ownership.xml · derivative · entry 1 Dutia Suren G · CIK 0001514063 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-02-16 F1 · security: The options vest in full on February 16, 2022. F1 · derivative.exercise_date: The options vest in full on February 16, 2022. Read SEC document |
| October 06, 2020 Filed Oct 9, 2020 20:08 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 35,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001213900-20-030795 · ownership.xml · derivative · entry 1 Dutia Suren G · CIK 0001514063 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-10-06 F1 · security: The options vest in full on October 6, 2021. F1 · derivative.exercise_date: The options vest in full on October 6, 2021. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:06 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 25,000 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001213900-20-017080 · ownership.xml · derivative · entry 1 Dutia Suren G · CIK 0001514063 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-07-07 F1 · security: The options vest in full on July 7, 2021. F1 · derivative.exercise_date: The options vest in full on July 7, 2021. Read SEC document |
| October 08, 2019 Filed Oct 10, 2019 20:08 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 25,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001213900-19-020113 · ownership.xml · derivative · entry 1 Dutia Suren G · CIK 0001514063 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-10-08 F1 · security: The options vest in full on October 8, 2020. F1 · derivative.exercise_date: The options vest in full on October 8, 2020. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 20:08 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 15,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001213900-18-012190 · ownership.xml · derivative · entry 1 Dutia Suren G · CIK 0001514063 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-09-04 F1 · security: The options vest in full on the first anniversary of the vesting commencement date, September 4, 2019. F1 · derivative.exercise_date: The options vest in full on the first anniversary of the vesting commencement date, September 4, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.